Tag: Press Releases,SITC 2017,cancer immunotherapy,immunotherapy biomarkers,lung cancer testing,melanoma testing
-
Biodesix Oral Presentation At SITC: Testing Methodology May Identify Primary Immunotherapy Resistance In Patients
Preliminary Data Indicate Primary Resistance May Be Overcome by Combination Therapies Boulder, Colorado, November 7, 2017… Biodesix® chief technology officer, Dr. Heinrich Roder, will give an oral presentation discussing a proprietary test development methodology that uses machine learning to correlate MALDI-ToF mass spectra from patient pre-treatment serum with clinical outcomes and benefit from therapy, specifically immunotherapies.…